Skip NavigationSkip to Content
Return Return to Search Results

Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer among Premenopausal Women

  1. Author:
    Eliassen, A. H.
    Spiegelman, D.
    Xu, X.
    Keefer, L. K.
    Veenstra, T. D.
    Barbieri, R. L.
    Willett, W. C.
    Hankinson, S. E.
    Ziegler, R. G.

  2. Author Address

    [Eliassen, A. Heather; Willett, Walter C.; Hankinson, Susan E.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA. [Barbieri, Robert L.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Eliassen, A. Heather; Spiegelman, Donna; Willett, Walter C.; Hankinson, Susan E.] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA USA. [Spiegelman, Donna] Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA. [Willett, Walter C.] Harvard Univ, Sch Med, Dept Nutr, Boston, MA USA. [Xu, Xia; Veenstra, Timothy D.] NCI, Lab Prote & Analyt Technol, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA. [Hankinson, Susan E.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA. [Keefer, Larry K.] NCI, Comparat Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA. [Ziegler, Regina G.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.;Eliassen, AH (reprint author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA;heather.eliassen@channing.harvard.edu
    1. Year: 2012
    2. Date: Feb
  2. Journal: Cancer Research
    1. 72
    2. 3
    3. Pages: 696-706
  4. Type of Article: Article
  5. ISSN: 0008-5472
  1. Abstract:

    Endogenous estrogens and estrogen metabolism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited. We examined 15 urinary estrogens/estrogen metabolites and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II (NHSII). From 1996 to 1999, urine was collected from 18,521 women during the mid-luteal menstrual phase. Breast cancer cases (N = 247) diagnosed between collection and June 2005 were matched to two controls each (N = 485). Urinary estrogen metabolites were measured by liquid chromatography-tandem mass spectrometry and adjusted for creatinine level. Relative risks (RR) and 95% confidence intervals (CI) were estimated by multivariate conditional logistic regression. Higher urinary estrone and estradiol levels were strongly significantly associated with lower risk (top vs. bottom quartile RR: estrone = 0.52; 95% CI, 0.30-0.88; estradiol = 0.51; 95% CI, 0.30-0.86). Generally inverse, although nonsignificant, patterns also were observed with 2- and 4-hydroxylation pathway estrogen metabolites. Inverse associations generally were not observed with 16-pathway estrogen metabolites and a significant positive association was observed with 17-epiestriol (top vs. bottom quartile RR 1.74; 95% CI, 1.08-2.81; P-trend = 0.01). In addition, there was a significant increased risk with higher 16-pathway/parent estrogen metabolite ratio (comparable RR 1.61; 95% CI, 0.99-2.62; P-trend = 0.04). Other pathway ratios were not significantly associated with risk except parent estrogen metabolites/non-parent estrogen metabolites (comparable RR 0.58; 95% CI, 0.35-0.96; P-trend = 0.03). These data suggest that most mid-luteal urinary estrogen metabolite concentrations are not positively associated with breast cancer risk among premenopausal women. The inverse associations with parent estrogen metabolites and the parent estrogen metabolite/non-parent estrogen metabolite ratio suggest that women with higher urinary excretion of parent estrogens are at lower risk. Cancer Res; 72(3); 696-706. (C) 2011 AACR.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/0008-5472.can-11-2507
  3. View record in Web of Science®
  4. WOS: 000300405900014

Library Notes

  1. Fiscal Year: FY2011-2012
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel